Northwest Biotherapeutics
Bethesda, Maryland, United States · Biotechnology, Healthcare, research
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The C
Key facts
- Headquarters
- Bethesda, Maryland, United States
- Employees
- 25
- Industries
- Biotechnology, Healthcare, research
- Status
- Public (NWBO)
- Website
- nwbio.com
- Company page
Recent activity at Northwest Biotherapeutics
- : SEC 8-K (1.01):
- : Northwest Biotherapeutics Appoints New Quality Assurance Manager and Director of Information Technologies
- : Northwest Biotherapeutics Partners with SPIMACO for Collaboration in Saudi Arabia on DCVax® Products.
- : SEC 8-K (1.01): On July 29, 2026, Northwest Biotherapeutics entered into a $4.9 million convertible Promissory Note financing with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP. The Note, which has a term of 12 months and carries an Original Issue Discount of five percent, does not require payments until maturity and is convertible at the option of the holder at a discount to the market price. Additionally, the Company and Yorkville have a standby equity subscription agreement allowing NW Bio to require Yorkville to subscribe for up to $50 million of common shares at a discount to market price after the Note is repaid or converted. The company has not committed to using this arrangement but sees it as a potential funding option for key milestones. Yorkville also obtained a warrant to purchase up to $2 million of shares at $0.205 per share as part of the transaction.
- : SEC 8-K (7.01):
- : SEC 8-K (2.01):
- : SEC 8-K (8.01):
- : SEC 8-K (1.01): On November 14, 2025, Northwest Biotherapeutics, Inc. entered into a $5 million convertible Promissory Note financing with YA II PN, Ltd., managed by Yorkville Advisors Global, LP. The proceeds from this financing will be allocated towards the construction and equipment costs for the company's first Grade C manufacturing suite in its Sawston, UK facility, as well as for ongoing operations. The Note, which has a 12-month term, includes a five percent Original Issue Discount and is convertible at the holder's option at a slight discount to the prevailing market price, with conversion limits set at approximately one fifth of the Note amount per calendar month unless the conversion price exceeds $0.29.
- : SEC 8-K (1.01): On November 14, 2025, Northwest Biotherapeutics, Inc. entered into a $5 million convertible Promissory Note financing with YA II PN, Ltd., managed by Yorkville Advisors Global, LP. The funds will be utilized for construction and equipment costs at the company's new Grade C manufacturing suite in Sawston, UK, as well as for ongoing operations. The Note has a 12-month term, with no payments due until maturity, and it carries a five percent Original Issue Discount with no interest charged. The Note can be converted by the holder at a discount to market price, with monthly conversion limits set at one fifth of the total amount.
- : SEC 8-K (1.01): On October 27, 2025, Northwest Biotherapeutics, Inc. entered into a Commercial Loan Agreement with Streeterville Capital, LLC for $5,505,000. The Loan Agreement has a 22-month maturity with no repayments for the first 8 months, starting repayments on June 26, 2026, in 14 equal monthly installments at a rate of 110% of the pro rata amount, plus accrued interest. The interest rate on the loan is set at 8% per annum. Funds from this loan will be utilized for the Company’s ongoing business operations, facilitating strategic growth initiatives. Additionally, the agreement includes provisions for pre-payment with a 10% charge and customary default terms.
Northwest Biotherapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2024 | Convertible Note | $5.0M |
| Nov 2021 | Funding Round | $15.0M |
| Sep 2020 | Venture | Undisclosed |
| Jan 2018 | Seed | $880K |
| May 2017 | Pre-Seed | $52K |
Leadership
- Daniel Moore, Senior Director of Information Technology
- Linda Powers, Executive Officer, Director
- Alton Boynton, Executive Officer, Director
- J Black, Director
- Jerry Jasinowski, Director
- Navid Malik, Director
Verified email and direct lines for Northwest Biotherapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Northwest Biotherapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Northwest Biotherapeutics in the news
- Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference - PR Newswire (Oct 06, 2026)
- NHS teams help produce an experimental cancer vaccine. Partners are exploring more UK sites. - Stock Titan (Oct 08, 2026)
- Northwest Biotherapeutics Announces Expansion of Its Technical Team - PR Newswire (Oct 26, 2026)
- Northwest Biotherapeutics, Inc. (NWBO) stock price, news, quote and history - Yahoo Finance UK (May 19, 2017)
- Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd. - PR Newswire (Aug 27, 2025)
- Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company - PR Newswire (Aug 06, 2026)
- Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed - PR Newswire (Oct 24, 2025)
Companies similar to Northwest Biotherapeutics
- BioLineRx Ltd · Biotechnology, Healthcare, research
- Kernal Biologics · Biotechnology, Healthcare, research
- Aarvik Therapeutics · Biotechnology, Healthcare, research
- Zentalis Pharmaceuticals · Biotechnology, Healthcare, research
- Avenda Health, Inc. · Biotechnology, Healthcare
About Northwest Biotherapeutics: questions and answers
What does Northwest Biotherapeutics do?
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The C
Where is Northwest Biotherapeutics headquartered?
Northwest Biotherapeutics is headquartered in Bethesda, Maryland, United States.
How many employees does Northwest Biotherapeutics have?
Northwest Biotherapeutics has about 25 employees.
Has Northwest Biotherapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Northwest Biotherapeutics. The most recent, Convertible Note of $5.0M, was in Dec 2024.
What is the latest news on Northwest Biotherapeutics?
On Oct 30, 2026, SEC 8-K (1.01):
Is Northwest Biotherapeutics a public company?
Yes. Northwest Biotherapeutics is publicly traded under the ticker NWBO.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy